Joanna Sadowska: Bayer’s Asundexian Reduces Ischemic Stroke Risk in Phase 3 Trial
Joanna Sadowska, Biopharma Account Specialist, shared on LinkedIn:
”Big News – Bayer’s asundexian reduces ischaemic stroke risk in Phase 3 clinical trial
Bayer has announced positive Phase 3 results from the OCEANIC-STROKE study evaluating asundexian, an investigational once-daily oral Factor XIa inhibitor, for secondary stroke prevention.
This is the first study that successfully completed Phase 3 for Factor XIa.
Approximately 12 million people worldwide experience a stroke each year, with 20-30% being recurrent strokes.
One in five stroke survivors will have another stroke within five years, and these recurrent strokes tend to be more disabling and carry a higher mortality risk than first strokes.
Asundexian is a direct Factor XIa inhibitor designed to reduce thrombus formation that can lead to vessel blockage.
It has a novel mechanism targeting the coagulation pathway differently from current antiplatelet therapies.
Asundexian has received FDA Fast Track Designation for stroke prevention in this patient population.”
Stay informed with Hemostasis Today.
-
Dec 2, 2025, 10:59Catherine Thieblemont: Reappointed as Head of Department – A Joy, A Responsibility, and A Challenge that Remains Intact
-
Dec 2, 2025, 10:06Maeva May Shares Stroke Association’s New Research Strategy that Launched at UKSF2025
-
Dec 2, 2025, 10:00Jennifer Ficenec: What Happens to Blood Products After Hospitals Say No?
-
Dec 2, 2025, 09:55Marilena Vrana Reflects on A Year of Growth, Gratitude, and Collective Strength
-
Dec 2, 2025, 09:51Time to Refocus on NSTEMI․ Why This State-of-the-Art Review Matters
-
Dec 2, 2025, 09:51Arsène Mekinian: Corticosteroid Tapering Strategies Show No Difference
-
Dec 2, 2025, 09:49George Touma: Sirolimus DCBs Will Eventually Replace Paclitaxel
-
Dec 2, 2025, 09:49Professor Erwin Loh: Amino Acid Reduces Alzheimer’s Plaques
-
Dec 2, 2025, 09:47How does the ISBT Mentorship Platform Work ?